Production (Stage)
Beam Therapeutics Inc.
BEAM
$16.83
-$0.41-2.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -75.16% | 110.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -75.16% | 110.72% | |||
| Cost of Revenue | -84.49% | 7.62% | |||
| Gross Profit | 88.42% | 10.77% | |||
| SG&A Expenses | -2.51% | 8.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.57% | 7.73% | |||
| Operating Income | -19.24% | 6.07% | |||
| Income Before Tax | -20.94% | 6.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.94% | 6.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.94% | 6.53% | |||
| EBIT | -19.24% | 6.07% | |||
| EBITDA | -20.26% | 6.37% | |||
| EPS Basic | -13.86% | 7.00% | |||
| Normalized Basic EPS | -13.05% | 6.12% | |||
| EPS Diluted | -13.54% | 6.73% | |||
| Normalized Diluted EPS | -13.05% | 6.12% | |||
| Average Basic Shares Outstanding | 6.22% | 0.50% | |||
| Average Diluted Shares Outstanding | 6.22% | 0.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||